Medtronic beat Wall Street estimates for third-quarter profit on Tuesday, partly helped by demand for its diabetes devices, but shares fell nearly 5% in premarket trading as it saw softer sales in its medical surgical unit.

Medtronic (MDT) beat estimates for profits in the last quarter thanks to strong demand for diabetes and heart devices. Earnings per share

Medtronic posted a strong profit for Q3 of fiscal year 2025, though shares were down as its cardiac ablation product success was offset by weaker sales from its medical-surgical business. The medtech giant brought in revenue of $8.